Genetron Health has signed an exclusive agreement with Shanghai Fosun Pharmaceutical’s (Fosun Pharma) subsidiary Jiangsu Fosun Pharmaceutical to commercialise the Seq-MRD molecular diagnostic assay in China.
Seq-MRD has been designed to detect minimal residual disease (MRD) in patients with select hematologic cancers.
It has been optimised with One-step Seq technology from Genetron, which enables PCR reaction and reduces contamination risk as well as false-positive results.
Using this feature, along with Genetron’s fully automated bioinformatics solutions, the new assay achieves accuracy, cost-efficiency, high throughput, uniformity and fast turnaround time.
Genetron Health stated that the collaboration marks its first product launch for hematologic cancer and MRD detection in China.
Under the terms of the deal, both companies will jointly market and promote Seq-MRD in hematologic-focused hospitals and clinics in the country’s designated territories.
They aim to serve patients suffering with lymphoid malignancies, including chronic lymphoid leukaemia (CLL), acute lymphoblastic leukaemia (ALL), and multiple myeloma (MM).
Fosun Pharma chairman and CEO Wu Yifang said: “Our partnership’s goal is to increase Seq-MRD’s market penetration and turn it into a standardised next-generation sequencing (NGS)-based MRD test.
“We believe that our capabilities and network can maximise the product’s commercialisation potential. More importantly, we are excited about the prospects of better MRD testing, and the significant clinical value that it could offer to cancer survivors.”
As part of the collaboration, Jiangsu Fosun Pharma will employ a sales force focused on hematologic cancer.
Meanwhile, Genetron Health will provide commercial and technical support, including marketing, conducting training related to the product and promoting scientific studies.
In May, Genetron collaborated with Siemens Healthineers to enable the application of its S5 platform and lung cancer eight-gene IVD assay in Chinese hospitals.